Physician profile
Carlos E Munoz
NPI 1043269285
$18,177.99
in general payments reported to CMS, 2019-2025
60 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,516 · 2020: $2,620 · 2021: $2,673 · 2022: $2,579 · 2023: $3,487 · 2024: $2,979 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,739 · Education: $49.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,739.27 |
| Education | $49.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,919.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,883.92 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,855.67 | 2019-2025 | |
| Lilly USA, LLC | $1,460.64 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,158.76 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $831.51 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $824.92 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $747.13 | 2021-2025 | |
| Amarin Pharma, INC. | $724.53 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $635.43 | 2020-2023 | |
| Pfizer INC. | $570.34 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $528.41 | 2019-2023 | Verquvo, Steglujan, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $496.17 | 2019-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $368.78 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $344.79 | 2019-2022 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.